{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T01:01:44Z","timestamp":1769216504956,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Over the past years, EGFR tyrosine kinase inhibitors (TKI) revolutionized treatment response. 1st-generation (reversible) EGFR TKI and later the 2nd \u2013generation irreversible EGFR TKI Afatinib were aimed to improve treatment response. Nevertheless, diverse resistance mechanisms develop within the first year of therapy. Here, we evaluate the prevalence of acquired resistance mechanisms towards reversible and irreversible EGFR TKI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Rebiopsies of patients after progression to EGFR TKI therapy (&gt;\u20096\u2009months) were targeted to histological and molecular analysis. Multiplexed targeted sequencing (NGS) was conducted to identify acquired resistance mutations (e.g. EGFR p.T790M). Further, Fluorescence in situ hybridisation (FISH) was applied to investigate the status of bypass mechanisms like, MET or HER2 amplification.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred twenty-three rebiopsy samples of patients that underwent first-line EGFR TKI therapy (PFS \u22656\u2009months) were histologically and molecularly profiled upon clinical progression. The<jats:italic>EGFR<\/jats:italic>p.T790M mutation is the major mechanism of acquired resistance in patients treated with reversible as well as irreversible EGFR TKI. Nevertheless a statistically significant difference for the acquisition of T790M mutation has been identified: 45% of afatinib- vs 65% of reversible EGFR TKI treated patients developed a T790M mutation (<jats:italic>p<\/jats:italic>-value 0.02). Progression free survival (PFS) was comparable in patients treated with irreversible<jats:italic>EGFR<\/jats:italic>irrespective of the sensitising primary mutation or the acquisition of p.T790M.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The<jats:italic>EGFR<\/jats:italic>p.T790M mutation is the most prominent mechanism of resistance to reversible and irreversible EGFR TKI therapy. Nevertheless there is a statistically significant difference of p.T790M acquisition between the two types of TKI, which might be of importance for clinical therapy decision.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-020-06920-3","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T08:04:22Z","timestamp":1589270662000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2870-5606","authenticated-orcid":false,"given":"Svenja","family":"Wagener-Ryczek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina","family":"Heydt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliane","family":"S\u00fcptitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Michels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Falk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Alidousty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Fassunke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela Angelika","family":"Ihle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Tiemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Heukamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Merkelbach-Bruse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"issue":"1","key":"6920_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9\u201329.","journal-title":"CA Cancer J Clin"},{"issue":"25","key":"6920_CR2","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380\u20138.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"6920_CR3","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1038\/onc.2009.198","volume":"28","author":"AF Gazdar","year":"2009","unstructured":"Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(Suppl 1):S24\u201331.","journal-title":"Oncogene."},{"issue":"9","key":"6920_CR4","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1159\/000354627","volume":"36","author":"J K\u00f6hler","year":"2013","unstructured":"K\u00f6hler J, Schuler M. Afatinib, Erlotinib and Gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. Oncol Research and Treatment. 2013;36(9):510\u20138.","journal-title":"Oncol Research and Treatment"},{"issue":"10","key":"6920_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947\u201357.","journal-title":"N Engl J Med"},{"issue":"2","key":"6920_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121\u20138.","journal-title":"Lancet Oncol"},{"issue":"18","key":"6920_CR7","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","volume":"372","author":"PA Janne","year":"2015","unstructured":"Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689\u201399.","journal-title":"N Engl J Med"},{"issue":"3","key":"6920_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1371\/journal.pmed.0020073","volume":"2","author":"W Pao","year":"2005","unstructured":"Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):22.","journal-title":"PLoS Med"},{"key":"6920_CR9","doi-asserted-by":"crossref","unstructured":"Nagano T, Tachihara M, Nishimura Y. Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy. Cells. 2018;7(11):212.","DOI":"10.3390\/cells7110212"},{"issue":"10","key":"6920_CR10","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","volume":"2","author":"K Takezawa","year":"2012","unstructured":"Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2012;2(10):922\u201333.","journal-title":"Cancer Discov"},{"issue":"7","key":"6920_CR11","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/1541-7786.MCR-16-0482","volume":"15","author":"T Yamaoka","year":"2017","unstructured":"Yamaoka T, Ohmori T, Ohba M, Arata S, Murata Y, Kusumoto S, et al. Distinct Afatinib resistance mechanisms identified in lung adenocarcinoma harboring an EGFR mutation. Mol Cancer Res. 2017;15(7):915\u201328.","journal-title":"Mol Cancer Res"},{"issue":"7","key":"6920_CR12","doi-asserted-by":"publisher","first-page":"E526","DOI":"10.21037\/jtd.2018.06.83","volume":"10","author":"S Shinohara","year":"2018","unstructured":"Shinohara S, Ichiki Y, Fukuichi Y, Honda Y, Kanayama M, Taira A, et al. Squamous cell carcinoma transformation from adenocarcinoma as an acquired resistance after the EGFR TKI therapy in (EGFR-mutated) non-small cell lung cancer. J Thorac Dis. 2018;10(7):E526\u2013E31.","journal-title":"J Thorac Dis"},{"issue":"10","key":"6920_CR13","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1634\/theoncologist.2015-0073","volume":"20","author":"DF Heigener","year":"2015","unstructured":"Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, M\u00e4rten A, et al. Afatinib in non-small cell lung Cancer harboring uncommon EGFR mutations pretreated with reversible EGFR inhibitors. Oncologist. 2015;20(10):1167\u201374.","journal-title":"Oncologist"},{"issue":"2","key":"6920_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/CCO.0000000000000164","volume":"27","author":"BC Liao","year":"2015","unstructured":"Liao BC, Lin CC, Yang JC. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015;27(2):94\u2013101.","journal-title":"Curr Opin Oncol"},{"issue":"8","key":"6920_CR15","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","volume":"19","author":"HA Yu","year":"2013","unstructured":"Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240\u20137.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"6920_CR16","doi-asserted-by":"publisher","first-page":"12404","DOI":"10.18632\/oncotarget.7189","volume":"7","author":"SG Wu","year":"2016","unstructured":"Wu SG, Liu YN, Tsai MF, Chang YL, Yu CJ, Yang PC, et al. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget. 2016;7(11):12404\u201313.","journal-title":"Oncotarget."},{"issue":"40","key":"6920_CR17","doi-asserted-by":"publisher","first-page":"68123","DOI":"10.18632\/oncotarget.19243","volume":"8","author":"K Tanaka","year":"2017","unstructured":"Tanaka K, Nosaki K, Otsubo K, Azuma K, Sakata S, Ouchi H, et al. Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor\u2013na\u00efve patients with non\u2013small cell lung cancer harboring EGFR mutations. Oncotarget. 2017;8(40):68123\u201330.","journal-title":"Oncotarget."},{"issue":"2","key":"6920_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/cjp2.66","volume":"3","author":"M Wittersheim","year":"2017","unstructured":"Wittersheim M, Heydt C, Hoffmann F, Buttner R. KRAS mutation in papillary fibroelastoma: a true cardiac neoplasm? J Pathol Clin Res. 2017;3(2):100\u20134.","journal-title":"J Pathol Clin Res"},{"issue":"7","key":"6920_CR19","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1097\/JTO.0000000000000570","volume":"10","author":"K Konig","year":"2015","unstructured":"Konig K, Peifer M, Fassunke J, Ihle MA, Kunstlinger H, Heydt C, et al. Implementation of amplicon parallel sequencing leads to improvement of diagnosis and therapy of lung Cancer patients. J Thorac Oncol. 2015;10(7):1049\u201357.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"6920_CR20","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00428-018-2305-5","volume":"472","author":"SE Gultekin","year":"2018","unstructured":"Gultekin SE, Aziz R, Heydt C, Senguven B, Zoller J, Safi AF, et al. The landscape of genetic alterations in ameloblastomas relates to clinical features. Virchows Arch. 2018;472(5):807\u201314.","journal-title":"Virchows Arch"},{"issue":"4","key":"6920_CR21","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1158\/1078-0432.CCR-14-0450","volume":"21","author":"HU Schildhaus","year":"2015","unstructured":"Schildhaus HU, Schultheis AM, Ruschoff J, Binot E, Merkelbach-Bruse S, Fassunke J, et al. MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung. Clin Cancer Res. 2015;21(4):907\u201315.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"6920_CR22","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/j.jtho.2016.06.032","volume":"11","author":"M Campo","year":"2016","unstructured":"Campo M, Gerber D, Gainor JF, Heist RS, Temel JS, Shaw AT, et al. Acquired resistance to first-line Afatinib and the challenges of prearranged progression biopsies. J Thorac Oncol. 2016;11(11):2022\u20136.","journal-title":"J Thorac Oncol"},{"issue":"suppl_1","key":"6920_CR23","doi-asserted-by":"publisher","first-page":"i20","DOI":"10.1093\/annonc\/mdx704","volume":"29","author":"J Remon","year":"2018","unstructured":"Remon J, Steuer CE, Ramalingam SS, Felip E. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Ann Oncol. 2018;29(suppl_1):i20\u2013i7.","journal-title":"Ann Oncol"},{"issue":"11","key":"6920_CR24","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1055\/a-0647-9835","volume":"72","author":"F Griesinger","year":"2018","unstructured":"Griesinger F, Radke S, Luers A, Deschler-Baier B, Kimmich M, Sebastian M, et al. Strategies to overcome acquired resistance to EGFR-TKI therapy based on T790M specific substances using Osimertinib as an example. Pneumologie. 2018;72(11):774\u201381.","journal-title":"Pneumologie."},{"key":"6920_CR25","first-page":"2017","volume":"3370","author":"N El Kadi","year":"2018","unstructured":"El Kadi N, Wang L, Davis A, Korkaya H, Cooke A, Vadnala V, et al. The EGFR T790M mutation is acquired through AICDA-mediated deamination of 5-methylcytosine following TKI treatment in lung cancer. Cancer Res. 2018;3370:2017.","journal-title":"Cancer Res"},{"issue":"75","key":"6920_CR26","doi-asserted-by":"publisher","first-page":"3002003","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):3002003.","journal-title":"Sci Transl Med"},{"issue":"1","key":"6920_CR27","first-page":"67","volume":"4","author":"EL Stewart","year":"2015","unstructured":"Stewart EL, Tan SZ, Liu G, Tsao MS. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res. 2015;4(1):67\u201381.","journal-title":"Transl Lung Cancer Res"},{"issue":"31","key":"6920_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1073\/pnas.1203530109","volume":"109","author":"K Ohashi","year":"2012","unstructured":"Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012;109(31):6.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"suppl_1","key":"6920_CR29","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29(suppl_1):i10\u2013i9.","journal-title":"Ann Oncol"},{"issue":"3","key":"6920_CR30","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1136\/esmoopen-2016-000060","volume":"1","author":"F Morgillo","year":"2016","unstructured":"Morgillo F, Della Corte CM, Fasano M, Ciardiello F. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. 2016;1(3):2016\u2013000060.","journal-title":"ESMO Open"},{"issue":"17","key":"6920_CR31","doi-asserted-by":"publisher","first-page":"5530","DOI":"10.1158\/1078-0432.CCR-10-2571","volume":"17","author":"GR Oxnard","year":"2011","unstructured":"Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res. 2011;17(17):5530\u20137.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"6920_CR32","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1158\/1078-0432.CCR-11-1080","volume":"17","author":"GR Oxnard","year":"2011","unstructured":"Oxnard GR, Janjigian YY, Arcila ME, Sima CS, Kass SL, Riely GJ, et al. Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. Clin Cancer Res. 2011;17(19):6322\u20138.","journal-title":"Clin Cancer Res"},{"key":"6920_CR33","doi-asserted-by":"crossref","unstructured":"Tian Y, Zhao J, Ren P, Wang B, Zhao C, Shi C, et al. Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma. PLoS One. 2018;13(11):e0201682.","DOI":"10.1371\/journal.pone.0201682"},{"issue":"175346661880865","key":"6920_CR34","doi-asserted-by":"crossref","first-page":"175346661880865","DOI":"10.1177\/1753466618808659","volume":"12","author":"B Ricciuti","year":"2018","unstructured":"Ricciuti B, Baglivo S, De Giglio A, Chiari R. Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience. Ther Adv Respir Dis. 2018;12(1753466618808659):1753466618808659.","journal-title":"Ther Adv Respir Dis"},{"key":"6920_CR35","doi-asserted-by":"publisher","first-page":"36458","DOI":"10.1038\/srep36458","volume":"6","author":"N Matsuo","year":"2016","unstructured":"Matsuo N, Azuma K, Sakai K, Hattori S, Kawahara A, Ishii H, et al. Association of EGFR exon 19 deletion and EGFR-TKI treatment duration with frequency of T790M mutation in EGFR-mutant lung Cancer patients. Sci Rep. 2016;6:36458.","journal-title":"Sci Rep"},{"issue":"3","key":"6920_CR36","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4040","volume":"22","author":"AN Hata","year":"2016","unstructured":"Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016;22(3):262\u20139.","journal-title":"Nat Med"},{"issue":"27","key":"6920_CR37","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.2217\/fon-2018-0711","volume":"14","author":"MJ Hochmair","year":"2018","unstructured":"Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, et al. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. Future Oncol. 2018;14(27):2861\u201374.","journal-title":"Future Oncol"},{"key":"6920_CR38","first-page":"1","volume":"14","author":"I Attili","year":"2018","unstructured":"Attili I, Karachaliou N, Conte P, Bonanno L, Rosell R. Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. Expert Rev Anticancer Ther. 2018;14:1\u201310.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10","key":"6920_CR39","first-page":"000000000000049","volume":"15","author":"F Griesinger","year":"2018","unstructured":"Griesinger F, Roeper J. Epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer: what is the preferred first-line therapy? Curr Opin Oncol. 2018;15(10):0000000000000495.","journal-title":"Curr Opin Oncol"},{"key":"6920_CR40","first-page":"1061","volume-title":"Cancer Discovery","author":"Osimertinib May Be an Effective First-Line Therapy in EGFR-Mutant NSCLC","year":"2017","unstructured":"Osimertinib May Be an Effective First-Line Therapy in EGFR-Mutant NSCLC. Cancer Discovery. 2017;7(10):1061-."},{"issue":"4","key":"6920_CR41","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.jtho.2016.11.2235","volume":"12","author":"X Mao","year":"2017","unstructured":"Mao X, Zhang Z, Zheng X, Xie F, Duan F, Jiang L, et al. Capture-based targeted Ultradeep sequencing in paired tissue and plasma samples demonstrates differential subclonal ctDNA-releasing capability in advanced lung Cancer. J Thorac Oncol. 2017;12(4):663\u201372.","journal-title":"J Thorac Oncol"},{"issue":"35","key":"6920_CR42","doi-asserted-by":"publisher","first-page":"13081","DOI":"10.1073\/pnas.0801523105","volume":"105","author":"PJ Campbell","year":"2008","unstructured":"Campbell PJ, Pleasance ED, Stephens PJ, Dicks E, Rance R, Goodhead I, et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A. 2008;105(35):13081\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"6920_CR43","first-page":"2018","volume":"8","author":"S Kohsaka","year":"2018","unstructured":"Kohsaka S, Petronczki M, Solca F, Maemondo M. Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing. Future Oncol. 2018;8(10):2018\u20130736.","journal-title":"Future Oncol"},{"key":"6920_CR44","first-page":"1078","volume":"25","author":"M Offin","year":"2018","unstructured":"Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, et al. Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers. Clin Cancer Res. 2018;25:1078\u20130432.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06920-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-06920-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06920-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T14:18:52Z","timestamp":1666534732000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-06920-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6920"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-06920-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]},"assertion":[{"value":"7 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Collection of tissue was approved by the Medical Ethics Committee of the University Hospital Cologne and all study participants gave written informed consent as part of the Network Genomic Medicine (NGM).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"408"}}